Biased Ligands. Better Drugs.

BLAST-AHF trial design

Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor : Rationale and Design of the BLAST-AHF Study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail. 2015 Mar;3(3):193-201. doi: 10.1016/j.jchf.2014.09.008. Epub 2015 Jan 28.

G. Michael Felker, MD, MHS, Javed Butler, MD, MPH, Sean P. Collins, MD, MSc, Gad Cotter, MD, Beth A. Davison, PhD, Justin A. Ezekowitz, MBBCh, MSc, Gerasimos Filippatos, MD, Phillip D. Levy, MD, Marco Metra, MD, Piotr Ponikowski, MD, PhD, David G. Soergel, MD, John R. Teerlink, MD, Jonathan D. Violin, PhD, Adriaan A. Voors, MD, PhD, Peter S. Pang, MD

View PDF

Copyright © Trevena, Inc.